NEW YORK (GenomeWeb News) – Ventana is developing a companion diagnostic test for an oncology drug developed by Seattle Genetics and Millennium Pharmaceuticals under a deal announced today.
The companion diagnostic being developed by Ventana, a Roche company, will be for identifying patients who best respond to Adcetris (brentuximab vedotin) based on CD30 expression levels in their tissue specimens. Under the terms of the agreement, Ventana will develop, manufacture, and commercialize the test.